Table 4:
Commercial assays
Instrument/Assay | Antigen | Isotype | Center/Institution | Regulatory Status |
---|---|---|---|---|
Abbott Alinity | Spike | IgM | Mount Sinai | FDA EUA granted |
Abbott Architect | Spike, Nucleocapsid | IgG | Cedars-Sinai* | FDA EUA granted |
Beckman Coulter Access | Spike | IgG | Arizona State University | FDA EUA granted |
Beckman Coulter Access | Spike | IgM | Arizona State University | FDA EUA granted |
DiaSorin Liaison | Spike | IgG | Feinstein/Northwell, Kaiser, The Ohio State University | FDA EUA granted |
DiaSorin Liaison | Spike | IgM | Feinstein/Northwell | FDA EUA granted |
Kantaro SeroKlir | Spike, RBD | IgG | Mount Sinai | FDA EUA granted |
Kantaro Quantitative SARS-CoV-2 | Spike, RBD | IgG | Mount Sinai | FDA EUA pending |
Meso Scale Discovery | Spike, Nucleocapsid | IgG, IgM | University of Alabama - Birmingham, CVVR/BIDMC/Harvard, Johns Hopkins University, Stanford | RUO |
Roche Elecsys Anti-SARS-CoV-2 | Nucleocapsid | Total Ig | University of Minnesota, Feinstein/Northwell | FDA EUA granted |
Roche Elecsys Anti-SARS-CoV-2 S | RBD | Total Ig | University of Minnesota, Feinstein/Northwell | FDA EUA granted |
Siemens Atellica | Spike | Total Ig | Kaiser, The Ohio State University | FDA EUA granted |
Samples sent to Abbott Diagnostics for testing
BIDMC: Beth Israel Deaconess Medical Center; CVVR: Center for Virology and Vaccine Research; EUA: Emergency use authorization; FDA: Food and Drug Administration; RBD: Receptor binding domain; RUO: Research use only